Vir Biotechnology

VIR · NASDAQ

$10.74+$0.01 (+0.09%)TodayMarket closed · Oct 21, 4:49 AM ET

Prev close $10.73

Latest news

NewsOct 14, 12:58 PM ETVandana Singh
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
NewsOct 14, 8:40 AM ET
Vir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties
NewsOct 14, 8:34 AM ET
Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens
Press releaseOct 14, 8:30 AM ETBusiness Wire
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
Press releaseOct 8, 8:30 AM ETBusiness Wire
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
Press releaseOct 7, 8:30 AM ETBusiness Wire
Vir Biotechnology Appoints David Liu as Chief Medical Officer
Press releaseOct 5, 4:05 PM ETBusiness Wire
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026
Press releaseOct 1, 8:30 AM ETBusiness Wire
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
Press releaseAug 31, 4:05 PM ETBusiness Wire
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NewsAug 5, 4:15 PM ET
Vir Biotechnology Q2 EPS $0.47 Beats $0.18 Estimate, Sales $238.946M Beat $216.456M Estimate
Press releaseAug 5, 4:05 PM ETBusiness Wire
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Press releaseJul 24, 8:30 AM ETBusiness Wire
Vir Biotechnology Announces Chief Financial Officer Transition
Press releaseJul 22, 4:05 PM ETBusiness Wire
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
Press releaseJun 10, 4:05 PM ETBusiness Wire
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
Press releaseMay 18, 4:05 PM ETBusiness Wire
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
Press releaseMay 14, 10:55 AM ETGlobe Newswire
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
Press releaseMay 6, 4:05 PM ETBusiness Wire
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
Press releaseMay 5, 4:05 PM ETBusiness Wire
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
Press releaseApr 23, 4:05 PM ETBusiness Wire
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
Press releaseApr 16, 8:05 AM ETBusiness Wire
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
Press releaseApr 13, 8:05 AM ETBusiness Wire
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Press releaseMar 5, 9:00 AM ETPRNewswire
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
Press releaseFeb 26, 4:05 PM ETBusiness Wire
Vir Biotechnology to Participate in Upcoming Investor Conferences
NewsFeb 26, 8:03 AM ETAvi Kapoor
C3.ai Posts Downbeat Results, Joins Trade Desk, FTAI Aviation And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
NewsFeb 26, 7:05 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Press releaseFeb 25, 10:31 PM ETBusiness Wire
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
Press releaseFeb 24, 4:05 PM ETBusiness Wire
Vir Biotechnology Announces Proposed Public Offering of Common Stock
NewsFeb 24, 1:05 PM ETAvi Kapoor
These Analysts Boost Their Forecasts On Vir Biotechnology
NewsFeb 24, 12:38 PM ETAvi Kapoor
Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views
NewsFeb 24, 12:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
Press releaseFeb 24, 10:17 AM ETGlobe Newswire
Biotech and Big Tech Drive the Morning Narrative
NewsFeb 24, 10:07 AM ETAvi Kapoor
Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday
NewsFeb 24, 8:31 AM ETRishabh Mishra
Stock Market Today: S&P 500 Futures Slip As Dow, Nasdaq 100 Gain Following Trump's Tariff Threat — Whirlpool, Uber, HP In Focus (UPDATED)
NewsFeb 24, 7:28 AM ET
Market-Moving News for February 24th
NewsFeb 24, 7:05 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Press releaseFeb 23, 5:14 PM ETBusiness Wire
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments

Vir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties

Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

Vir Biotechnology Appoints David Liu as Chief Medical Officer

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Vir Biotechnology Q2 EPS $0.47 Beats $0.18 Estimate, Sales $238.946M Beat $216.456M Estimate

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Vir Biotechnology Announces Chief Financial Officer Transition

Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results

Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors

Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026

"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

Earnings Scheduled For May 6, 2026

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types

Vir Biotechnology to Participate in Upcoming Investor Conferences

C3.ai Posts Downbeat Results, Joins Trade Desk, FTAI Aviation And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

Vir Biotechnology Announces Proposed Public Offering of Common Stock

These Analysts Boost Their Forecasts On Vir Biotechnology

Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views

12 Health Care Stocks Moving In Tuesday's Intraday Session

Biotech and Big Tech Drive the Morning Narrative

Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday

Stock Market Today: S&P 500 Futures Slip As Dow, Nasdaq 100 Gain Following Trump's Tariff Threat — Whirlpool, Uber, HP In Focus (UPDATED)

Market-Moving News for February 24th

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results